After a couple of days with losses, Regenicin, Inc. (OTC:RGIN) got the up move at once. Yesterday, the stock gained 
approximately 47% on the market and its traded volume jumped up.
At this point, there is only one reason for the volume spike – promotions. It was just yesterday when RGIN was promoted by stocktwiter.com, spreading out gaining alerts about the stock. The campaign cost $15.000, paid by The Broadsmoore Group, who certainly managed to influence RGIN stock price.
In fact, the alerts started a bit earlier, when RGIN was included in a promotional letter by Quality Stocks on June 3. Though, it was not enough to pump up the stock price. Now, it is interesting how long the new campaign will hold the current up move.
Regenicin, Inc. is a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Historical records show that the company has not released any news lately, apart from its quarterly report. The 10-Q came up in end-May and at fist sight it looked quite promising. Though, on a closer look the situation was completely different.[BANNER]
Despite the fact that Regenicin had more assets than liabilities in its balance, as of March 31 this year its accumulated deficit jumped over $3 million. At the same time, the net loss reached $2 million, while revenues were still missing.
Considering the poor results, the management claims that Regenicin does not have sufficient cash to operate its business at the current level for the next twelve months. Thus, it is dependent on funding operations through the issuance of convertible debt and private sale of equity securities. However, there is no guarantee any of these could be ensured, which raises substantial doubt about the company’s ability to continue as a going concern.
